US 11,896,663 B2
Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
Johannes Petrus Maria Langedijk, Amsterdam (NL); Danielle Van Manen, Alphen aan den Rijn (NL); Jort Vellinga, Leiden (NL); Frank Wegmann, Leiden (NL); Benoit Christophe Stephan Callendret, The Hague (NL); Anders Krarup, Glostrup (DK); and Jörn Stitz, Cologne (DE)
Assigned to Janssen Vaccines & Prevention B.V., Leiden (NL)
Filed by Janssen Vaccines & Prevention B.V., Leiden (NL)
Filed on Mar. 3, 2021, as Appl. No. 17/190,569.
Application 17/190,569 is a division of application No. 16/440,463, filed on Jun. 13, 2019, granted, now 10,973,907.
Application 16/440,463 is a division of application No. 15/380,123, filed on Dec. 15, 2016, granted, now 10,369,214, issued on Aug. 6, 2019.
Claims priority of application No. 15200138 (EP), filed on Dec. 15, 2015; and application No. 16194124 (EP), filed on Oct. 17, 2016.
Prior Publication US 2021/0220468 A1, Jul. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/21 (2006.01); C07K 14/16 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); C12N 15/861 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/21 (2013.01) [C07K 14/005 (2013.01); C07K 14/162 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); C12N 15/861 (2013.01); C12N 2710/10343 (2013.01); C12N 2740/16111 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16171 (2013.01); C12N 2740/16234 (2013.01)] 6 Claims
 
1. An RNA molecule encoding a synthetic HIV envelope protein comprising SEQ ID NO: 8, or SEQ ID NO: 8 having one or more mutations selected from the group consisting of (i) I529P, (ii) K480E, and (iii) a combination of EK479-48ORRRR, I529P, A471C and T575C.